Movement Alert｜ImmunityBio Rises 5.66% in Regular Trading, AUA Positive Efficacy Data Fuels Rebound After Two-Day Selloff

Market Focus05-26

On May 26, ImmunityBio rose 5.66% in regular trading, trading at $7.585/share, with trading volume of $24.38 million. The stock rebounded following consecutive declines of 7.89% and 5.23% on May 21 and May 22 respectively.

The rebound was supported by positive efficacy comparison data presented at the American Urological Association 2026 Annual Meeting. ImmunityBio disclosed that its Nai combined with BCG therapy demonstrated favorable complete response rates compared to Nadofaragene and TAR-200 in BCG-unresponsive non-muscle invasive bladder cancer patients. Additionally, a health economics analysis presented at ISPOR 2026 showed that ANKTIVA plus BCG achieves higher sustained complete response rates at lower cost versus TAR-200.

Following concentrated profit-taking that drove the prior two-session decline on elevated volume, selling pressure appears to have been largely absorbed. The current session saw trading volume stabilize near recent levels, suggesting renewed buyer interest as the market re-prices the clinical data catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191305962?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191305962","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio Rises 5.66% in Regular Trading, AUA Positive Efficacy Data Fuels Rebound After Two-Day Selloff","media":"Market Focus","content":"<p><p>On May 26, ImmunityBio rose 5.66% in regular trading, trading at $7.585/share, with trading volume of $24.38 million. The stock rebounded following consecutive declines of 7.89% and 5.23% on May 21 and May 22 respectively.</p><p>The rebound was supported by positive efficacy comparison data presented at the American Urological Association 2026 Annual Meeting. ImmunityBio disclosed that its Nai combined with BCG therapy demonstrated favorable complete response rates compared to Nadofaragene and TAR-200 in BCG-unresponsive non-muscle invasive bladder cancer patients. Additionally, a health economics analysis presented at ISPOR 2026 showed that ANKTIVA plus BCG achieves higher sustained complete response rates at lower cost versus TAR-200.</p><p>Following concentrated profit-taking that drove the prior two-session decline on elevated volume, selling pressure appears to have been largely absorbed. The current session saw trading volume stabilize near recent levels, suggesting renewed buyer interest as the market re-prices the clinical data catalysts.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio Rises 5.66% in Regular Trading, AUA Positive Efficacy Data Fuels Rebound After Two-Day Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio Rises 5.66% in Regular Trading, AUA Positive Efficacy Data Fuels Rebound After Two-Day Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-26 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 26, ImmunityBio rose 5.66% in regular trading, trading at $7.585/share, with trading volume of $24.38 million. The stock rebounded following consecutive declines of 7.89% and 5.23% on May 21 and May 22 respectively.</p><p>The rebound was supported by positive efficacy comparison data presented at the American Urological Association 2026 Annual Meeting. ImmunityBio disclosed that its Nai combined with BCG therapy demonstrated favorable complete response rates compared to Nadofaragene and TAR-200 in BCG-unresponsive non-muscle invasive bladder cancer patients. Additionally, a health economics analysis presented at ISPOR 2026 showed that ANKTIVA plus BCG achieves higher sustained complete response rates at lower cost versus TAR-200.</p><p>Following concentrated profit-taking that drove the prior two-session decline on elevated volume, selling pressure appears to have been largely absorbed. The current session saw trading volume stabilize near recent levels, suggesting renewed buyer interest as the market re-prices the clinical data catalysts.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1191305962","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191305962","pubTimestamp":1779804116,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 26, ImmunityBio rose 5.66% in regular trading, trading at $7.585/share, with trading volume of $24.38 million. The stock rebounded following consecutive declines of 7.89% and 5.23% on May 21...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"动向提示|ImmunityBio常规交易涨5.66%AUA积极疗效数据助推两日抛售后反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On May 26, ImmunityBio rose 5.66% in regular trading, trading at $7.585/share, with trading volume of $24.38 million. The stock rebounded following consecutive declines of 7.89% and 5.23% on May 21 and May 22 respectively.The rebound was supported by positive efficacy comparison data presented at the American Urological Association 2026 Annual Meeting. ImmunityBio disclosed that its Nai combined with BCG therapy demonstrated favorable complete response rates compared to Nadofaragene and TAR-200 in BCG-unresponsive non-muscle invasive bladder cancer patients. Additionally, a health economics analysis presented at ISPOR 2026 showed that ANKTIVA plus BCG achieves higher sustained complete response rates at lower cost versus TAR-200.Following concentrated profit-taking that drove the prior two-session decline on elevated volume, selling pressure appears to have been largely absorbed. The current session saw trading volume stabilize near recent levels, suggesting renewed buyer interest as the market re-prices the clinical data catalysts.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191305962","isCrawlerRequest":true}